{"id":908790,"date":"2025-11-12T10:20:10","date_gmt":"2025-11-12T15:20:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/"},"modified":"2025-11-12T10:20:10","modified_gmt":"2025-11-12T15:20:10","slug":"reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/","title":{"rendered":"Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CUPERTINO, Calif., Nov.  12, 2025  (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that the anti-inflammatory impacts of brilaroxazine from the Phase 3 RECOVER double-blind trial in patients with acute exacerbation of schizophrenia, and from the long-term open-label extension trial in clinically stable schizophrenia patients will be presented as a late-breaker poster presentation at the 2025 Neuroscience meeting taking place November 15\u201319, 2025 in San Diego, CA.<\/p>\n<p align=\"justify\">Details for the poster presentation can be found below:<\/p>\n<p align=\"justify\">\n        <strong>Title:<\/strong> Brilaroxazine treatment effects on BDNF and inflammatory cytokines in schizophrenia: RECOVER trial in acute and stable patients over 1 year<br \/><strong>Session Name:<\/strong> A.10. Schizophrenia<br \/><strong>Session Number:<\/strong> LBP010<br \/><strong>Date and Time:<\/strong> Saturday, November 15, 2025, 1:00 \u2013 5:00 PM PT<\/p>\n<p align=\"justify\">Abstracts and additional details can be found at the 2025 Neuroscience <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NOnIlM3Ict2E9ZN2B5ngqfKwPpp2RUDZUTt6tslfx-PV5sYcmU41rWCtHvva7_qq7e8jUd_1pfiSK_fMY-o27jnBDTm6DmkdX1d2oeLXfWM=\" rel=\"nofollow\" target=\"_blank\">website<\/a>.<\/p>\n<p><strong>About Reviva\u00a0<\/strong><br \/>Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva\u2019s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva\u2019s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.<\/p>\n<p>\n        <strong>Corporate Contact:<\/strong><br \/>\n        <br \/>Reviva Pharmaceuticals Holdings, Inc.<br \/>Laxminarayan Bhat, PhD\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ctX964cH7TJSkmd9TiuPWFHvZGheq_jDhpcOO03IOhyLGY2TxjaloZsaQ2EEv1vY7n8tveCxcaVXsR103YqmTuQqrocurGETVx7bKFln8wc=\" rel=\"nofollow\" target=\"_blank\">www.revivapharma.com<\/a><\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>LifeSci Advisors, LLC<br \/>PJ Kelleher<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NcODjDE2PqjPZDjXfu_4VG3oGtHNoh2un3mKBs051muBFMN2ziMh2gb18468dvpNYB4c-7gl80LhdTTi6hwsxcvtGkYBIiECwzeeb59S3dcKM0vUbNv3xajPwLyTXjhZ\" rel=\"nofollow\" target=\"_blank\">pkelleher@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzQ2OCM3MjU3Njc4IzUwMDA3NTM4MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWE0OGQ0YmUtY2ZlMy00NTllLThjNzUtYTRlZjM4NDBhY2NhLTUwMDA3NTM4MS0yMDI1LTExLTEyLWVu\/tiny\/Reviva-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CUPERTINO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that the anti-inflammatory impacts of brilaroxazine from the Phase 3 RECOVER double-blind trial in patients with acute exacerbation of schizophrenia, and from the long-term open-label extension trial in clinically stable schizophrenia patients will be presented as a late-breaker poster presentation at the 2025 Neuroscience meeting taking place November 15\u201319, 2025 in San Diego, CA. Details for the poster presentation can be found below: Title: Brilaroxazine treatment effects on BDNF and inflammatory cytokines in schizophrenia: RECOVER &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-908790","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CUPERTINO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that the anti-inflammatory impacts of brilaroxazine from the Phase 3 RECOVER double-blind trial in patients with acute exacerbation of schizophrenia, and from the long-term open-label extension trial in clinically stable schizophrenia patients will be presented as a late-breaker poster presentation at the 2025 Neuroscience meeting taking place November 15\u201319, 2025 in San Diego, CA. Details for the poster presentation can be found below: Title: Brilaroxazine treatment effects on BDNF and inflammatory cytokines in schizophrenia: RECOVER &hellip; Continue reading &quot;Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-12T15:20:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzQ2OCM3MjU3Njc4IzUwMDA3NTM4MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025\",\"datePublished\":\"2025-11-12T15:20:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\\\/\"},\"wordCount\":275,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3MzQ2OCM3MjU3Njc4IzUwMDA3NTM4MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\\\/\",\"name\":\"Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3MzQ2OCM3MjU3Njc4IzUwMDA3NTM4MQ==\",\"datePublished\":\"2025-11-12T15:20:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3MzQ2OCM3MjU3Njc4IzUwMDA3NTM4MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3MzQ2OCM3MjU3Njc4IzUwMDA3NTM4MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/","og_locale":"en_US","og_type":"article","og_title":"Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025 - Market Newsdesk","og_description":"CUPERTINO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that the anti-inflammatory impacts of brilaroxazine from the Phase 3 RECOVER double-blind trial in patients with acute exacerbation of schizophrenia, and from the long-term open-label extension trial in clinically stable schizophrenia patients will be presented as a late-breaker poster presentation at the 2025 Neuroscience meeting taking place November 15\u201319, 2025 in San Diego, CA. Details for the poster presentation can be found below: Title: Brilaroxazine treatment effects on BDNF and inflammatory cytokines in schizophrenia: RECOVER &hellip; Continue reading \"Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-12T15:20:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzQ2OCM3MjU3Njc4IzUwMDA3NTM4MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025","datePublished":"2025-11-12T15:20:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/"},"wordCount":275,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzQ2OCM3MjU3Njc4IzUwMDA3NTM4MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/","name":"Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzQ2OCM3MjU3Njc4IzUwMDA3NTM4MQ==","datePublished":"2025-11-12T15:20:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzQ2OCM3MjU3Njc4IzUwMDA3NTM4MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzQ2OCM3MjU3Njc4IzUwMDA3NTM4MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-to-present-anti-inflammatory-impacts-of-brilaroxazine-in-schizophrenia-from-the-recover-12-month-open-label-extension-trial-at-neuroscience-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=908790"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908790\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=908790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=908790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=908790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}